Skip to content Skip to sidebar Skip to footer
Subscribe Now
Insights+ EMA Marketing Authorization of New Drugs in September 2022
INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in September 2022

The EMA approved 7 New Chemical Entity (NCE) and 4 Biologic Drugs in Sept 2022, leading to treatments for patients and advances in the healthcare industryIn September 2022, the major highlights drugs were Imcivree approval for bardet-biedl syndrome, Opdualag for unresectable or metastatic melanoma, Ultomiris for generalised myasthenia gravisPharmaShots has compiled a list…
October 26, 20220Comments

Read more

Viewpoints_Garret Hampton
VIEWPOINTS

Garret Hampton, President, Clinical Sequencing & Oncology at Thermo Fisher Scientific Shares Insights from the Approval of the First NGS-Based Companion Diagnostic for HER2-Mutant NSCLC

Shots:Garret spoke about the approval of the first NGS-based companion diagnostic to aid in selecting NSCLC patients with HER2  activating mutations for treatment with ENHERTUGarret also talked about the Oncomine Dx Target Test and its availability for different targeted therapies in multiple geographiesThe interview highlights how Thermo Fisher is working to develop accessible CDx solutions…
October 25, 20220Comments

Read more

Viewpoints_Josh Rubel
VIEWPOINTS

Josh Rubel, CCO at MDClone, Shares Insights on the Partnership with MCI Onehealth to Accelerate Research through Global Clinical Intelligence Offering

Shots:Josh spoke about the collaboration with MCI Onehealth. The collaboration will provide access to high-value data insights as a service for an array of research, clinical, and data science needsJosh also talked about MDClone’s ADAMS platform which has a unique ability to convert datasets and cohorts of interest into synthetic files that are…
October 19, 20220Comments

Read more

Viewpoints_Jonathan Wall
VIEWPOINTS

Jonathan Wall, Co-founder & Interim CSO at Attralus Share Insights from its New Data Presented across its Amyloidosis Portfolio at the 2022 International Symposium on Amyloidosis

Shots:Jonathan spoke about the data presented by Attralus at the XVIII International Symposium on Amyloidosis (ISA) as both oral and poster presentationsJonathan also talked about its lead candidate, AT-01. He discussed the study design of the P-I/II clinical trial evaluating AT-01The interview highlights Attralus vision to develop innovative medicines to improve the…
October 17, 20220Comments

Read more